AstraZeneca PLC (AZN) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - General
EV/EBITDA
↓
15.76
↓-29% vs avg
5yr avg: 22.21
30Y Low3.2·High36.8
P/FCF
↓
24.05
↓-23% vs avg
5yr avg: 31.30
30Y Low5.5·High159.7
P/B Ratio
↑
5.85
+13% vs avg
5yr avg: 5.18
30Y Low1.9·High9.0
ROE
↑
22.9%
↓+76% vs avg
5yr avg: 13.0%
30Y Low0%·High42%
Debt/EBITDA
↓
1.53
↓-49% vs avg
5yr avg: 2.98
30Y Low0.1·High5.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AZN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AstraZeneca PLC trades at 27.9x earnings, 91% below its 5-year average of 326.5x, sitting at the 66th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 25%. On a free-cash-flow basis, the stock trades at 24.1x P/FCF, 23% below the 5-year average of 31.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $283.0B | $274.1B | $203.2B | $210.0B | $212.5B | $165.3B | $132.6B | $131.4B | $93.0B | $81.8B | $68.2B |
| Enterprise Value | $306.9B | $298.1B | $227.8B | $232.8B | $235.5B | $189.7B | $145.2B | $144.3B | $107.3B | $96.3B | $80.0B |
| P/E Ratio → | 27.91 | 26.83 | 57.78 | 35.29 | 64.56 | 1448.13 | 41.39 | 98.06 | 43.18 | 27.24 | 19.52 |
| P/S Ratio | 4.82 | 4.67 | 3.76 | 4.58 | 4.79 | 4.42 | 4.98 | 5.39 | 4.21 | 3.64 | 2.96 |
| P/B Ratio | 5.85 | 5.63 | 4.97 | 5.36 | 5.73 | 4.21 | 8.48 | 9.00 | 6.62 | 4.92 | 4.09 |
| P/FCF | 24.05 | 23.30 | 27.93 | 31.98 | 29.36 | 43.93 | 60.47 | 258.16 | 74.58 | 41.78 | 37.25 |
| P/OCF | 19.41 | 18.81 | 17.13 | 20.30 | 21.67 | 27.72 | 27.63 | 44.26 | 35.52 | 22.86 | 16.45 |
P/E links to full P/E history page with 30-year chart
AZN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
AstraZeneca PLC's enterprise value stands at 15.8x EBITDA, 29% below its 5-year average of 22.2x. The Healthcare sector median is 14.4x, placing the stock at a 10% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.08 | 4.21 | 5.08 | 5.31 | 5.07 | 5.45 | 5.92 | 4.86 | 4.29 | 3.48 |
| EV / EBITDA | 15.76 | 15.31 | 15.12 | 17.73 | 26.13 | 36.77 | 18.01 | 21.58 | 15.03 | 14.34 | 11.02 |
| EV / EBIT | 22.34 | 21.15 | 21.96 | 27.43 | 61.47 | 187.61 | 27.98 | 48.90 | 31.94 | 26.84 | 16.26 |
| EV / FCF | — | 25.34 | 31.31 | 35.45 | 32.54 | 50.41 | 66.19 | 283.42 | 86.03 | 49.17 | 43.69 |
AZN Profitability
Margins and return-on-capital ratios measuring operating efficiency
AstraZeneca PLC earns an operating margin of 23.4%. Operating margins have expanded from 17.9% to 23.4% over the past 3 years, signaling improving operational efficiency. ROE of 22.9% indicates solid capital efficiency. ROIC of 14.9% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9% | 81.9% | 81.1% | 82.0% | 72.1% | 66.8% | 80.1% | 79.8% | 77.7% | 80.8% | 82.1% |
| Operating Margin | 23.4% | 23.4% | 18.5% | 17.9% | 8.5% | 2.8% | 19.4% | 12.0% | 15.3% | 16.4% | 21.3% |
| Net Profit Margin | 17.5% | 17.5% | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% | 5.5% | 9.8% | 13.4% | 15.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.9% | 22.9% | 17.6% | 15.6% | 8.6% | 0.4% | 21.1% | 9.3% | 14.0% | 18.0% | 19.9% |
| ROA | 9.4% | 9.4% | 6.9% | 6.0% | 3.3% | 0.1% | 5.0% | 2.2% | 3.5% | 4.8% | 5.7% |
| ROIC | 14.9% | 14.9% | 11.8% | 10.1% | 4.6% | 1.7% | 13.9% | 7.9% | 8.5% | 9.3% | 13.2% |
| ROCE | 17.2% | 17.2% | 13.6% | 11.6% | 4.9% | 1.6% | 11.5% | 6.7% | 7.4% | 7.8% | 10.6% |
AZN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
AstraZeneca PLC carries a Debt/EBITDA ratio of 1.5x, which is manageable (54% below the sector average of 3.3x). Net debt stands at $24.0B ($29.7B total debt minus $5.7B cash). Interest coverage of 8.3x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.61 | 0.61 | 0.74 | 0.73 | 0.79 | 0.78 | 1.30 | 1.25 | 1.36 | 1.07 | 1.01 |
| Debt / EBITDA | 1.53 | 1.53 | 2.00 | 2.18 | 3.23 | 5.95 | 2.53 | 2.73 | 2.68 | 2.65 | 2.32 |
| Net Debt / Equity | — | 0.49 | 0.60 | 0.58 | 0.62 | 0.62 | 0.80 | 0.88 | 1.02 | 0.87 | 0.71 |
| Net Debt / EBITDA | 1.23 | 1.23 | 1.63 | 1.74 | 2.55 | 4.72 | 1.56 | 1.92 | 2.00 | 2.16 | 1.62 |
| Debt / FCF | — | 2.04 | 3.39 | 3.47 | 3.17 | 6.47 | 5.72 | 25.26 | 11.45 | 7.40 | 6.44 |
| Interest Coverage | 8.32 | 8.32 | 6.17 | 5.34 | 2.88 | 0.79 | 4.08 | 2.10 | 2.46 | 2.64 | 3.60 |
AZN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.94x is below 1.0, meaning current liabilities exceed current assets — though the company's $5.7B cash position helps mitigate short-term liquidity concerns. The current ratio has improved from 0.82x to 0.94x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.94 | 0.94 | 0.93 | 0.82 | 0.86 | 1.16 | 0.96 | 0.86 | 0.96 | 0.80 | 0.87 |
| Quick Ratio | 0.72 | 0.72 | 0.74 | 0.64 | 0.68 | 0.76 | 0.76 | 0.68 | 0.78 | 0.62 | 0.72 |
| Cash Ratio | 0.19 | 0.19 | 0.20 | 0.19 | 0.24 | 0.28 | 0.39 | 0.34 | 0.35 | 0.28 | 0.39 |
| Asset Turnover | — | 0.51 | 0.52 | 0.45 | 0.46 | 0.36 | 0.40 | 0.40 | 0.36 | 0.35 | 0.37 |
| Inventory Turnover | 1.62 | 1.62 | 1.93 | 1.52 | 2.64 | 1.38 | 1.32 | 1.54 | 1.71 | 1.42 | 1.77 |
| Days Sales Outstanding | — | 94.31 | 75.84 | 66.98 | 75.65 | 79.33 | 77.49 | 73.29 | 49.49 | 45.53 | 40.99 |
AZN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AstraZeneca PLC returns 2.0% to shareholders annually — split between a 1.8% dividend yield and 0.3% buyback yield. A payout ratio of 49.6% is moderate and appears sustainable, balancing shareholder returns with reinvestment capacity. The earnings yield of 3.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.8% | 1.9% | 2.3% | 2.1% | 2.1% | 2.3% | 2.7% | 2.7% | 3.7% | 4.3% | 5.2% |
| Payout Ratio | 49.6% | 49.6% | 65.8% | 75.2% | 132.7% | 3442.9% | 111.8% | 269.1% | 161.7% | 117.3% | 101.8% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.6% | 3.7% | 1.7% | 2.8% | 1.5% | 0.1% | 2.4% | 1.0% | 2.3% | 3.7% | 5.1% |
| FCF Yield | 4.2% | 4.3% | 3.6% | 3.1% | 3.4% | 2.3% | 1.7% | 0.4% | 1.3% | 2.4% | 2.7% |
| Buyback Yield | 0.3% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 2.0% | 2.1% | 2.3% | 2.1% | 2.1% | 2.3% | 2.7% | 2.7% | 3.7% | 4.3% | 5.2% |
| Shares Outstanding | — | $1.6B | $1.6B | $1.6B | $1.6B | $1.4B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B |
Peer Comparison
Compare AZN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AZNYou | $283B | 27.9 | 15.8 | 24.1 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 LLY | $921B | 42.5 | 30.6 | 102.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 BMY | $115B | 16.3 | 9.2 | 8.9 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 NVS | $277B | 20.2 | 13.5 | 15.7 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 SNY | $104B | 18.1 | 10.8 | 10.0 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
 GILD | $166B | 19.8 | 17.0 | 17.6 | 86.7% | 40.1% | 40.7% | 23.4% | 2.3 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 BIIB | $28B | 21.7 | 11.4 | 13.8 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full AZN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy AZN Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See AZN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AZN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AZN vs PFE
Side-by-side business, growth, and profitability comparison vs Pfizer Inc..
Start ComparisonAZN — Frequently Asked Questions
Quick answers to the most common questions about buying AZN stock.
What is AstraZeneca PLC's P/E ratio?
AstraZeneca PLC's current P/E ratio is 27.9x. The historical average is 24.9x. This places it at the 66th percentile of its historical range.
What is AstraZeneca PLC's EV/EBITDA?
AstraZeneca PLC's current EV/EBITDA is 15.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.1x.
What is AstraZeneca PLC's ROE?
AstraZeneca PLC's return on equity (ROE) is 22.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 24.1%.
Is AZN stock overvalued?
Based on historical data, AstraZeneca PLC is trading at a P/E of 27.9x. This is at the 66th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is AstraZeneca PLC's dividend yield?
AstraZeneca PLC's current dividend yield is 1.78% with a payout ratio of 49.6%.
What are AstraZeneca PLC's profit margins?
AstraZeneca PLC has 81.9% gross margin and 23.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does AstraZeneca PLC have?
AstraZeneca PLC's Debt/EBITDA ratio is 1.5x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.